Apellis Medical Hub
  • Science
    • PNH
    • Geographic Atrophy
    • ALS
    • C3G / IC -MPGN
    • CAD
    • HSCT-TMA
    • Pipeline
  • Medical Research
    • Scientific Focus
    • Investigator Initiated Trials
    • Collaborative Research
    • Medical Writing Grants
  • Congress & Manuscripts
    • Congress Presentations
    • Manuscripts
  • Resources
    • Medical Information
    • Early Access & Compassionate Use Program
    • Prescribing Information
  • Search
  • This website is intended only for use by U.S. Healthcare Professionals.
  • Menu Menu
  • Science
    • PNH
    • Geographic Atrophy
    • ALS
    • C3G / IC -MPGN
    • CAD
    • HSCT-TMA
    • Pipeline
  • Medical Research
    • Scientific Focus
    • Investigator Initiated Trials
    • Collaborative Research
    • Medical Writing Grants
  • Congress & Manuscripts
    • Congress Presentations
    • Manuscripts
  • Resources
    • Medical Information
    • Early Access & Compassionate Use Program
    • Prescribing Information
  • Search
  • This website is intended only for use by U.S. Healthcare Professionals.

Cold Agglutinin Disease (CAD)

CAD is a severe, chronic, rare blood disorder.1 It is a type of autoimmune hemolytic anemia (AIHA), which means that the body’s immune system attacks and destroys its own red blood cells by mistake.2

Symptoms of CAD may include fatigue, dizziness, chest pain, shortness of breath, anemia, transfusion requirements, dark urine and increased risk of thrombotic events like stroke or heart attack.2

In people with CAD, autoantibodies such as immunoglobin M (IgM) cause red blood cells to clump together when extremities (nose, ears, fingers, toes) are exposed to cold temperatures or when an individual with CAD has a compromised immune system or infection.3 Then, the complement cascade, which plays an important role in the immune system, is activated to destroy heathy red blood cells in a process called hemolysis.4,5

Excessive activation of the complement cascade can lead to the onset or progression of many diseases including CAD.6,7

Medical Resources

Clinical Trials

www.clinicaltrials.gov/ct2/show/NCT05096403?term=Sobi&cond=Cold+Agglutinin+Disease&draw=2&rank=1

References

  1. Sokol RJ, Hewitt S, Stamps BK. Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre. Br Med J (Clin Res Ed). 1981;282(6281):2023-2027.
  2. National Institute of Health (NIH), Genetic and Rare Diseases Information Center (GARD) Website www.rarediseases.info.nih.gov/diseases/6130/cold-agglutinin-disease. Accessed November 21, 2019.
  3. Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006;91(4):460-466.
  4. Cold agglutinin disease. Genetic and Rare Diseases Information Center Web site. www.rarediseases.info.nih.gov/diseases/6130/cold-agglutinin-disease. Accessed November 21, 2019.
  5. Reynaud Q, Durieu I, Dutertre M, et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. Autoimmun Rev. 2015;14(4):304-313.
  6. Morgan P, et al. Complement, a target for therapy in inflammatory and degenerative diseases. Nature Reviews Drug Discovery. 2015;14:857-877.
  7. Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol. 2007;171(3):715-727.

Report an Adverse Event or Product complaint

Please call 833-866-3346

Ask a Medical Question

Please click here or call
833-866-3346 (833-TO-MEDINFO)

Connect with an MSL

Set up a meeting with your
Medical Science Liaison

Privacy PolicyTerms and Conditions

©2023 Apellis Pharmaceuticals, Inc. All rights reserved. 08/23 MED-US-CORP-22-00001 v7.0
Scroll to top
You are now leaving ApellisMedicalHub.com

You are about to leave ApellisMedicalHub.com to visit a third-party website. We recommend reviewing the privacy policy and terms & conditions of any site you visit, as Apellis Pharmaceuticals, Inc. is not responsible for their content.

I agree
Landing

Landing

You are entering a website that is technical in nature and was created for scientific exchange with Healthcare Professionals. The content on this website may include scientific information about investigational compounds or indications that are not approved. Apellis does not support, endorse or recommend the unapproved use of any compound, including those discussed on this website.
Are you a Healthcare Professional licensed to practice in the country or region selected above? If you are not a Healthcare Professional, you will be redirected to www.apellis.com(Required)
Enter
Enter
Enter
Enter
Enter

Apellis Medical Affairs

You are entering a website that is technical in nature and was created for scientific exchange with U.S. Healthcare Professionals. The content on this website may include scientific information about investigational compounds or indications that are not approved. Apellis does not support, endorse or recommend the unapproved use of any compound, including those discussed on this website.

Are you a U.S. Healthcare Professional licensed to practice in the United States? 

If you are not a U.S. Healthcare Professional, you will be redirected to www.apellis.com